Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024)
Invivyd posted quarterly Total Non-Current Liabilities of $62.0 million for Q4 2024, up 21.49% year-on-year from $51.0 million in Q1 2024, and down 21.31% on a QoQ basis from $78.8 million in Q3 2024.
Invivyd (IVVD) has 5 years of Total Non-Current Liabilities data on file, last reported at $62.0 million in Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities rose 21.49% year-over-year to $62.0 million; the trailing twelve-month figure through Dec 2024 stood at $62.0 million (up 21.49% YoY), and the FY2024 full-year result was $62.0 million, up 21.49% from the prior year.
- Total Non-Current Liabilities for Q4 2024 stood at $62.0 million, down from $78.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $96.9 million in Q1 2022 and bottomed at $13.1 million in Q4 2020.
- The 5-year median for Total Non-Current Liabilities is $49.2 million (2022), against an average of $50.8 million.
- The widest annual swing landed in 2021, when Total Non-Current Liabilities jumped 374.4%; it then tumbled 56.18% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $13.1 million in 2020, then surged by 374.4% to $62.1 million in 2021, then plunged by 56.18% to $27.2 million in 2022, then soared by 87.57% to $51.0 million in 2023, then increased by 21.49% to $62.0 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $62.0 million (Q4 2024), $78.8 million (Q3 2024), and $36.7 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 61.98 Mn |
| Sep 30, 2024 | 78.76 Mn |
| Jun 30, 2024 | 36.70 Mn |
| Mar 31, 2024 | 36.97 Mn |
| Dec 31, 2023 | 51.01 Mn |
| Sep 30, 2023 | 27.72 Mn |
| Dec 31, 2022 | 27.20 Mn |
| Sep 30, 2022 | 47.30 Mn |
| Jun 30, 2022 | 69.77 Mn |
| Mar 31, 2022 | 96.88 Mn |
| Dec 31, 2021 | 62.07 Mn |
| Dec 31, 2020 | 13.08 Mn |